Cogent Biosciences, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Cogent Biosciences reports positive registrational trial results for bezuclastinib in SM and GIST, preparing for a Q2 2026 U.S. commercial launch, while expanding its precision therapy pipeline.
NASDAQ
Cogent Biosciences' 10-K filing reveals a year of significant clinical trial progress and pipeline expansion, balanced against substantial net losses and ongoing financial risks.
NASDAQ
Cogent Biosciences' 10-K filing outlines its capital structure, clinical programs, and intellectual property, highlighting its focus on precision therapies for genetically defined diseases.